昊海生物科技(06826.HK)斥1.35億人幣購醫學美容業務逾38%持股
昊海生物科技(06826.HK)公布,與Welly Bloom Limited及Refined Beauty Limited訂立購股協議,公司將收購歐華美科(天津)醫學科技合共約38.23%股權,代價為1.35億元人民幣(下同)。歐華美科(天津)醫學科技擁有射頻美膚設備、玻尿酸及幾丁糖生物材料,及激光美膚設備等三大產品線。
公司並訂立增資協議,向歐華美科(天津)醫學科技出資7,000萬元,公司於收購及增資後將持有其股權總額63.64%。根據增資協議,如歐華美科(天津)醫學科技的2021年、2022年及2023年淨利潤分別不少於600萬元、1,800萬元及3,000萬元,創始股東有權自其2023年度審計報告出具日期起計三個月內,要求公司以現金或通過發行代價股份收購創始股東持有之歐華美科(天津)醫學科技全部股權。
另外,公司與創始股東將成立一家作為期權池的有限合夥企業,以向創始股東及歐華美科(天津)醫學科技其他核心管理人員提供股權激勵。創始股東與公司將按零代價或中國法律允許的最低價格,分別向期權池轉讓其所持有的歐華美科(天津)醫學科技6.36%及3.64%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.